Echinacea
Echinacea purpurea, E. angustifolia, E. pallida
Popular cold remedy with genuinely conflicting evidence
Mixed evidence
🛡️Gut & Immune
Evidence tier
Mixed
Research weight
Citations
12 verified / 12
Classification
Gut & Immune
❝
What the evidence says. Conflicting results across studies; benefit uncertain.
What is Echinacea?
Echinacea (Echinacea purpurea, E. angustifolia, E. pallida) is a gut and immune supplement used for may modestly shorten or ease common-cold symptoms with some preparations, though effects are small and inconsistent. NutriDex grades the human evidence as Mixed. Echinacea is a genus of North American coneflowers (most commonly E. purpurea) widely marketed to prevent and treat the common cold and other respiratory infections. The evidence is genuinely mixed: the authoritative 2014 Cochrane review found no significant benefit for prevention and only weak, inconsistent signals for treatment, while several more recent meta-analyses report reductions in infection recurrence and antibiotic use. Much of the favorable recent data comes from analyses funded by or affiliated with manufacturers, and a major obstacle across all studies is the extreme variability between products in species, plant part, extraction method, and active-compound content, which makes results hard to generalize. Any clinical benefit, if real, appears small and preparation-specific rather than a class effect. Echinacea is generally well tolerated for short-term use in adults, but it is not a proven cold preventive and should not replace established care.
Purported Benefits
✓May modestly shorten or ease common-cold symptoms with some preparations, though effects are small and inconsistent
✓Some meta-analyses suggest reduced incidence of recurrent respiratory infections and lower antibiotic use, but these are largely industry-linked
✓Possible reduction in cold/respiratory-infection complications such as otitis media in children (preliminary)
✓Generally well tolerated short-term in adults
✓No reliable evidence it prevents colds in the general population
Evidence by outcome
The same supplement can be well-proven for one use and unproven for another — here is the human evidence graded outcome by outcome.
| Outcome | Evidence | Effect | Studies |
|---|---|---|---|
| Common cold prevention in general populationAuthoritative 2014 Cochrane review found no significant reduction in number of people catching a cold. | Moderate | — no effect · negligible | 1 |
| Treatment / shortening of cold symptomsCochrane found only weak inconsistent treatment effects; some RCTs show shorter remission but results are preparation-specific. | Mixed | ↔ mixed · small | 3 |
| Recurrent respiratory infections & antibiotic useMeta-analyses report ~32% lower RTI occurrence and less antibiotic use, but data are largely manufacturer-linked. | Mixed | ↑ benefit · moderate | 2 |
| Pediatric URTI / otitis media incidenceChildren's meta-analysis shows lower URTI and otitis media, but more adverse events and unclear safety. | Preliminary | ↑ benefit · small | 2 |
Dosing & Compounds
Typical Dose
No standardized dose; trials commonly use 300–500 mg dried extract or 2.5 mL liquid tincture 2–3x daily, or pressed juice of E. purpurea aerial parts, started at first cold symptoms and continued up to ~10 days. Potency varies enormously between products.
Active Compounds
Safety & Cautions
Generally well tolerated for short-term use in adults; most common effects are mild gastrointestinal upset, rash, or unpleasant taste. Allergic reactions can occur and may be serious, especially in people allergic to plants in the Asteraceae/daisy family (ragweed, marigolds, chrysanthemums); rare cases of anaphylaxis, asthma, and angioedema have been reported, so people with atopy or asthma should use caution. Because echinacea stimulates immune activity, it is traditionally avoided in autoimmune diseases (e.g., lupus, rheumatoid arthritis, MS) and in people taking immunosuppressants (e.g., transplant recipients, those on biologics). It may inhibit/induce CYP450 enzymes (notably CYP3A4 and CYP1A2), so it can interact with drugs metabolized by these pathways; caution with narrow-therapeutic-index medications. Safety in pregnancy and breastfeeding is not established, so avoidance is prudent. The 2025 pediatric meta-analysis noted increased adverse events in children and an unclear safety profile, so use in young children should be supervised. Product quality and potency vary widely, and it should not delay or replace evidence-based medical care for significant infections. Educational only — always check with your doctor or pharmacist before combining Echinacea with any medicine.
Echinacea drug interactions
Known or theoretical interactions between Echinacea and common medications — educational, not exhaustive. Always check with your doctor or pharmacist before combining Echinacea with any medicine.
Caution
May stimulate immune activity and theoretically blunt immunosuppressant therapy (transplant/autoimmune).
Echinacea up-regulates cytokine and immune-cell activity, opposing immunosuppression. NIH ODS — Echinacea
Key Studies ★ 12 studies
Meta-analysis
Gancitano et al. 2024 (ERA-PRIMA, Antibiotics)
✓ PubMed
Meta-analysis of 30 trials (39 comparisons, 5,652 subjects) found Echinacea reduced monthly RTI occurrence (RR 0.68, 95% CI 0.61-0.77) and proportion with >=1 RTI (RR 0.75, 95% CI 0.69-0.81), cut recurrent infections (RR 0.60), RTI complications (RR 0.44, 95% CI 0.36-0.54), and need for antibiotics (RR 0.60), with total antibiotic days reduced ~70% (IRR 0.29); alcoholic extracts of freshly harvested E. purpurea were strongest (80% reduction in antibiotic days). Adverse events equal to control.
Meta-analysis
Yuan et al. 2021 (J Integrative Medicine)
✓ PubMed
Overview of 11 Cochrane systematic reviews with Bayesian network meta-analysis of influenza-prevention interventions classified Echinacea as 'probably beneficial' for reducing influenza incidence (alongside oseltamivir, zanamivir, and Ganmao capsule), while garlic and vaccines showed high-quality benefit; no intervention reduced hospitalization.
Cochrane systematic review
24 trials, ~4,600 participants (Cochrane systematic review)
✓ PubMed
Echinacea showed no statistically significant reduction in the number of people catching a cold and only weak, inconsistent treatment effects, with the authors concluding any benefit is small at best.
Systematic review and meta-analysis
30 RCTs, 39 comparisons, 5,652 subjects (meta-analysis)
✓ Full text
Echinacea was associated with a 32% lower monthly respiratory-infection occurrence (RR 0.68, 95% CI 0.61–0.77) and reduced antibiotic need (RR 0.60, 95% CI 0.39–0.93), though the study was part-funded by a manufacturer (A.Vogel).
Systematic review and meta-analysis
9 RCTs, 3,169 children (systematic review and meta-analysis)
✓ PubMed
In children, E. purpurea was associated with lower URTI incidence (RR 0.81, 95% CI 0.75–0.87) and fewer otitis media episodes (RR 0.56, 95% CI 0.44–0.73), but adverse events were more frequent (RR 1.38, 95% CI 1.08–1.78) and the safety profile was deemed unclear.
Meta-analysis
Shah et al. 2007 (Lancet Infectious Diseases)
✓ PubMed
Meta-analysis of 14 studies found Echinacea decreased the odds of developing the common cold by 58% (OR 0.42, 95% CI 0.25-0.71) and reduced cold duration by 1.4 days (95% CI -2.2 to -0.6) versus placebo.
RCT
Frontiers in Medicine 2023
✓ Source
In an RCT of 409 adults (246 treated for RTI), higher-dose Echinacea formulations shortened mean time to remission (9.6 vs 11.0 days, p<0.001) and increased PCR-confirmed viral clearance by day 10 (70% vs 53%, p=0.046) versus conventional preventive doses.
RCT
Commission/Frontiers Med 2023
✓ Full text
Randomized blinded controlled trial in 409 healthy adults comparing high-dose novel Echinacea purpurea formulations (up to 16,800 mg/day extract days 1-3) versus conventional dosing for acute respiratory tract infection treatment.
RCT
Ogal 2021 (pediatric prevention RCT)
✓ Full text
In children aged 4-12, Echinacea purpurea prevented 32.5% of respiratory tract infection episodes versus vitamin C (OR 0.52) and reduced antibiotic need (5.8% vs 15.3% of children).
RCT
Jawad et al. 2012 (Evid Based Complement Alternat Med)
✓ PubMed
4-month randomized, double-blind, placebo-controlled trial (n=755) of E. purpurea extract (Echinaforce) for cold prevention: reduced total cold episodes, cumulated cold days (149 vs 293 days for placebo), and pain-killer-medicated episodes; significantly inhibited virally confirmed colds, especially enveloped-virus and recurrent infections, with good safety/tolerability.
Review
Alexandrova 2026
✓ PubMed
A Review of the Properties of Clinically Evaluated Plant-Derived Agents in the Treatment of Respiratory Infections
Product quality analysis
Critical analysis of marketed German Echinacea products
✓ Full text
Analysis found wide variation and frequent shortfalls in declared active-compound content across commercial Echinacea products, underscoring why clinical results are inconsistent and not transferable between preparations.